Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin

Journal of Urology

Volumn 165, Issue 1, 2001, Pages 263-270

  Mizutani, Yoichi ^a,b   Nakao, Masahiro ^a,b   Ogawa, Osamu ^a,b   Yoshida, Osamu ^a,b   Bonavida, Benjamin ^a,b   Miki, Tsuneharu ^a,b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bladder; Bladder neoplasms; Carboplatin; Cisplatin; Drug resistance

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; MITOMYCIN C; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CELL KILLING; CONTRAST SENSITIVITY; CYTOTOXICITY; DRUG EFFECT; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIGAND BINDING; MOLECULAR INTERACTION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0034747649     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-200101000-00076     Document Type: Article

References (51)

1. Lethal effect of the anti-Fas antibody in mice
2. Apoptosis in the pathogenesis and treatment of diseases
3. Identification and characterization of a new member of the TNF family that induces apoptosis
4. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
5. Death receptors: Signaling and modulation
6. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
7. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer
8. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity
9. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II)
10. Prognostic significance of soluble Fas in the serum of patients with bladder cancer
11. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes
12. Short-term culture of exfoliated cell from the urine of patients with bladder tumors
13. Fine structure of cultured epithelial cells derived from voided urine of normal adults
14. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or antiinterleukin-6-receptor monoclonal antibody
15. Overcoming TNF-α resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and TNF-α. Role of TNF-α mRNA downregulation in tumor cell sensitization
16. Characterization of the cell death process induced by staurosporine in human neuroblastoma cell lines
17. A study of the protective effect of chloride salts on cisplatin nephrotoxicity
18. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide
19. Synergy, additivism and antagonism in immunosuppression
20. A method for testing for synergy with any number of agents
21. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
22. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
23. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
24. Overcoming CDDP resistance of human ovarian tumor cells by combination treatment with CDDP and TNF-α
25. Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells
26. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells
27. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells
28. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells
29. The role of DNA repair in the recovery of human cells from cisplatin toxicity
30. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines
31. The receptor for the cytotoxic ligand TRAIL
32. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
33. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes
34. Inactivation of bcl-2 by phosphorylation
35. Activation of apoptosis by APO-2 ligand is independent of FADD but blocked by crmA
36. ICE-like proteases/caspases are involved in TRAIL-induced apoptosis of melanoma and leukemia cells
37. Inhibition of death receptor signals by cellular FLIP
38. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
39. Structure activity relationships of the antitumor platinum coordination complexes
40. Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and transdiamminedichloroplatinum (II)
41. Interactions between mammalian cell DNA and inorganic platinum compounds
42. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis
43. Modulation of NF-κB, p53 and bcl-2 in apoptosis induced by cisplatin in HeLa cells
44. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
45. p53-dependent and independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha
46. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage
47. Surface expression of TRAIL/Apo-2 ligand in activated T and B cells
48. TRAIL/Apo-2 ligand-induced apoptosis in human T cells
49. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells
50. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
51. Modulation by cisdiamminedichloroplatinum (II) (CDDP) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to blood natural killer (NK) cells and lymphokine activated killer (LAK) cells